论文信息 - Oral BCG vaccine in Crohn's disease.

Oral BCG vaccine in Crohn's disease.

In a randomised double-blind trial over one year oral BCG has been compared with a control preparation in the treatment of chronic Crohn's disease. Overall assessment scores deteriorated in nine of 22 patients taking BCG, and 11 of 26 in the control group (P = 0.25); this deterioration was great enough to be regarded as a clinical relapse in three patients taking BCG and in seven taking the control preparation (P greater than 0.1). No significant benefit from oral BCG treatment has been demonstrated.

[1] R. Summers,et al. National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.

[2] J. Lennard-jones,et al. DOUBLE-BLIND WITHDRAWAL TRIAL OF AZATHIOPRINE AS MAINTENANCE TREATMENT FOR CROHN'S DISEASE , 1978, The Lancet.

[3] A. Segal,et al. LEVAMISOLE IN THE TREATMENT OF CROHN'S DISEASE , 1977, The Lancet.

[4] F. Vicary,et al. Cell-mediated immunity and transfer factor in Crohn's disease. , 1976, British medical journal.

[5] F Kern,et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[6] H. Spiro,et al. Treatment of Crohn's disease with azathioprine: a controlled evaluation. , 1974, Gastroenterology.

[7] P. Lagrange,et al. Immunopotentiation with BCG. I. Immune response to different strains and preparations. , 1973, Journal of the National Cancer Institute.

[8] D. Bainton,et al. Controlled trial of azathioprine in Crohn's disease. , 1971, Lancet.

[9] J. A. Myers. BCG vaccination. , 1948, American review of tuberculosis.